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To determine if local monitoring data on vancomycin use directed quality improvement and decreased
vancomycin use or vancomycin-resistant enterococci (VRE), we analyzed data from 50 intensive-care
units (ICUs) at 20 U.S. hospitals reporting data on antimicrobial-resistant organisms and antimicrobial
agent use. We compared local data with national benchmark data (aggregated from all study hospitals).
After data were adjusted for changes in prevalence of methicillin-resistant Staphylococcus aureus,
changes in specific prescriber practice at ICUs were associated with significant decreases in vancomy-
cin use (mean decrease -48 defined daily doses per 1,000 patient days, p<0.001). These ICUs also
reported significant decreases in VRE prevalence compared with those not using unit-specific changes
in practice (mean decrease of 7.5% compared with mean increase of 5.7%, p<0.001). In this study,
practice changes focused towards specific ICUs were associated with decreases in ICU vancomycin
use and VRE prevalence.
he emerging problem of antimicrobial resistance in bacte-
rial pathogens is very complex (1,2). However, one com-
mon theme is that antecedent antimicrobial exposure exerts
selective pressure favoring the emergence of resistance (2).
Appropriate antimicrobial use is an integral component of any
program to slow the emergence and spread of antimicrobial-
resistant microorganisms in the health-care setting (1,3). The
optimal methods to reduce inappropriate or excessive antimi-
crobial use will differ by institution. Although many possible
interventions have been proposed (4), deciding which one is
the most effective in a particular setting can be difficult.
Despite guidelines from governmental and professional groups
(3,5–7), many hospitals have yet to institute any antimicrobial
use policies or programs to improve antimicrobial agent pre-
scribing (8). 
The Infectious Disease Society of America and the Society
for Healthcare Epidemiology of America Joint Committee on
the Prevention of Antimicrobial Resistance recently published
guidelines for the prevention of antimicrobial resistance in
hospitals (3). Two of the six broad recommendations were to
establish a system for monitoring bacterial resistance and anti-
biotic use and to establish practice guidelines and other institu-
tional policies to control the use of antibiotics and respond to
data from the monitoring system. Responding to data from a
local monitoring system, especially in the context of an exter-
nal benchmark, has been a successful way to create practice
changes to improve the quality of patient care (9,10). Efforts
have been made to improve outcomes for hospitalized
patients; success has been demonstrated with surgical site
infections and more recently, with catheter-related blood-
stream infections (11,12). In both examples, local infection
rates are compared with those of a sample that serves as an
external benchmark. Valid benchmarks for comparing antimi-
crobial use have not been well established (13). One example
of hospitals establishing a monitoring and benchmarking sys-
tem is Project Intensive Care Antimicrobial Resistance Epide-
miology (ICARE), a collaborative study between the Hospital
Infections Program (now the Division of Healthcare Quality
Promotion) at the Centers for Disease Control and Prevention
(CDC) and the Rollins School of Public Health of Emory Uni-
versity. During this 4-year study, a subset of hospitals partici-
pating in the National Nosocomial Infections Surveillance
(NNIS) system monitored antimicrobial use. We present data
from Project ICARE that demonstrate how hospitals used local
data and national benchmark data to effect practice changes
resulting in reduced vancomycin use and prevalence of vanco-
mycin-resistant enterococci (VRE) in intensive-care units
(ICUs). *Centers for Disease Control and Prevention, Atlanta, Georgia, USA;
and †Emory University, Atlanta, Georgia, USA




Hospitals that participate in the ICU surveillance compo-
nent of the NNIS system were invited to participate in the sec-
ond (January 1996 through December 1997) and third (April
1998 through July 1999) phases of Project ICARE; 55 ICUs
from 21 hospitals reported the required data to both the second
and third phase of Project ICARE. The surveillance methods
and definitions of the NNIS system (14,15) and Project
ICARE (13) have been previously described. As participants
in the NNIS system, ICUs had been previously categorized by
the types of patients served: coronary (CCU), medical
(MICU), general surgical (SICU), cardiothoracic, combined
medical-surgical (<80% of patients can be classified into a sin-
gle ICU patient type), neurosurgical, respiratory, trauma, burn,
or other.
Data Collection
Participating hospitals reported the grams of select antimi-
crobial agents administered to patients and the antimicrobial
susceptibility results of isolates recovered from clinical speci-
mens from hospitalized patients each month. Microbiologic
data were aggregated for each ICU separately, all non-ICU
inpatient wards combined, and all outpatient areas combined
(e.g., units that perform same-day surgery, simple diagnostic
procedures or therapy, urgent care, or emergency care). Phar-
macy data were reported for the same hospital strata, except
for outpatient areas for which pharmacy data were not avail-
able. Amounts of antimicrobial drugs reported were standard-
ized by conversion to defined daily doses; for parenteral
vancomycin, one daily dose was defined as 2 g. This analysis
includes both parenteral and oral (2% of total vancomycin use)
vancomycin. 
The microbiology laboratory reported antimicrobial sus-
ceptibility results for all enterococci and Staphylococcus
aureus isolates recovered from all clinical specimens, whether
associated with hospital- or community-acquired infection or
colonization. Duplicate isolates were excluded: these were
defined as isolates of the same organism with the same antimi-
crobial resistance pattern recovered from the same patient,
regardless of the site of isolation (e.g., blood, sputum, urine, or
wound), during the same calendar month. Susceptibility
reports from isolates obtained as part of infection-control sur-
veillance were excluded. When excluding these surveillance
isolates, VRE or methicillin-resistant S. aureus (MRSA) prev-
alence more closely reflects data routinely aggregated as part
of the cumulative susceptibility report (i.e., cumulative anti-
biogram). The validity of the susceptibility data submitted by
participating hospitals for VRE and MRSA  has previously
been confirmed through a proficiency testing program at these
laboratories and by confirmatory testing at the ICARE refer-
ence laboratory of up to 20 VRE and 20 MRSA isolates from
these hospitals (13,16). Enterococci were considered vanco-
mycin resistant if the MIC of vancomycin was 32 µg/mL or if
the zone diameter by disk diffusion was 14 mm. S. aureus
were considered oxacillin (methicillin) resistant if the MIC of
oxacillin was 4 µg/mL or if the zone diameter by disk diffu-
sion was 10 mm (17).
Feedback Data
In October 1997, a report of local monitoring data for each
hospital area compared to the national benchmark (i.e., aggre-
gate summary data from all 41 Phase 2 ICARE hospitals,
including 113 ICUs) was disseminated to each participating
hospital (18). The aggregate benchmark data included numeric
presentation of pooled means, medians, and key percentile dis-
tributions of the prevalence of selected antimicrobial-resistant
organisms, stratified by ICU areas combined, non-ICU–inpa-
tient areas combined, and outpatient areas combined (18). In
addition, the data for antimicrobial agent use were stratified by
the specific type of ICU (e.g., general-surgical separate from
cardiothoracic ICU, non-ICU–inpatient areas combined, and
outpatient areas combined) (18). Each individual hospital’s
report included raw data and pooled means of the same target
rates for each hospital area. Stratification of use and resistance
prevalence by different hospital areas, as described, provided a
valid benchmark by which hospitals were able to determine
how their usage and resistance prevalence compared with the
aggregate, when the data were adjusted for different patient
populations in these different hospital areas. 
To ascertain how the hospital infection-control staff used
the feedback report, they were surveyed in September 1999.
Information was collected on the use of the feedback report,
recognition of problem pathogens or excessive use of specific
antimicrobial agents, and specific practice changes. Questions
were open-ended to include any change in infection-control
practice (including hygienic practices, barrier precautions, and
antimicrobial control practices) from baseline practice (i.e.,
during pre-intervention period), rather than a description of
specific practices already in use. The infection-control practi-
tioner overseeing the surveillance activities responded to the
survey, with input from the infection-control committee, based
on recollection or meeting minutes.
Data Analysis
For this analysis, monthly data from each ICU were pooled
for the entire study period and for each period of the study
(i.e., pre-intervention and postintervention) by each ICU (data
from non-ICU–inpatient areas and outpatient areas are not
shown because of low statistical power). Pooled rates were
calculated for prevalence of VRE (percentage), MRSA (per-
centage), and vancomycin use (defined daily doses/1,000
patient-days). For example, the pooled mean rate of vancomy-
cin use was calculated for each ICU by dividing the total num-
ber of defined daily doses by the total number of patient-days
reported over the study period by that ICU, multiplied by
1,000, and thus expressed as defined daily doses per 1,000
patient-days. If <10 S. aureus or enterococci isolates were
tested for antimicrobial susceptibility from a specific ICURESEARCH
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during the study period, that ICU was excluded from further
analysis. 
Data were analyzed by SAS Release 6.12 Software (SAS
Institute Inc., Cary, NC). To assess the change in ICU-specific
prevalence of MRSA, VRE, and vancomycin use, the pre-
intervention rate was subtracted from the postintervention rate
(i.e., difference in rates). Differences in the percent VRE and
vancomycin use rate were evaluated by the paired t-test and
further compared by type of practice change by a paired t-test.
Frequency of MRSA in a hospital has been shown to be inde-
pendently associated with rates of vancomycin use (19). We
used linear regression modeling to determine which types of
practice changes were independently associated with changes
in vancomycin use in ICUs, after the data were adjusted for
each ICU and changes in MRSA prevalence by the GLM pro-
cedure (SAS Institute Inc.). Detection of potential influential
data points and their influence on main effect factors were also
assessed in the modeling process. All reported p values are
two-tailed. Analyses were repeated by using the relative
change of each parameter rather than difference in rates.
Results
Description of Sites
During the study period, 21 hospitals representing 55 ICUs
followed the surveillance protocol and reported at least 6
months of data by the time of the intervention and a median of
32 months (range 18–45) of data during the study period.
Twenty (95%) hospitals completed the intervention survey
representing the 50 ICUs included in this analysis. These hos-
pitals were from 18 states and had a median hospital bed size
of 351 (range 147–1,022); 13 (65%) reported an affiliation
with a teaching institution (i.e., major teaching centers), and 2
(10%) were Veterans Affairs Medical Centers. The ICUs
included 14 combined medical-surgical ICUs, 7 cardiac care
units, 7 MICUs, 8 general SICUs, 6 cardiothoracic ICUs, 4
neurosurgical ICUs, 3 pediatric ICUs, and 1 burn ICU. 
Use of Local Data Compared with Benchmark
Infection-control teams at all hospitals disseminated the
benchmark data to a variety of hospital committees and per-
sonnel (e.g., pharmacy and therapeutics, ICU personnel). This
feedback was usually in the form of a committee report or
memo. In addition to reporting, 12 (60%) hospitals changed
prescribing of vancomycin (i.e., prescriber practice change).
Eight (40%) hospitals reported at least one prescriber practice
change (many hospitals combined several hospitalwide
changes in prescriber practice) that was applied hospitalwide;
these changes encompassed 22 ICUs (Table). The hospital-
wide changes included evaluating periodic drug use (19 ICUs),
redistributing guidelines on appropriate uses of vancomycin
(20 ICUs) by newsletter or mail (9 ICUs), and requiring prior
approval for use of vancomycin (3 ICUs). In contrast, four
hospitals reported focused (i.e., ICU-specific) practice changes
in 11 ICUs; these included ICU-specific education in-service
sessions on appropriate vancomycin use (8 ICUs) and remov-
ing vancomycin as routine prophylaxis for cardiac surgery (2
ICUs). Both practice changes were reported in one ICU
(Table). 
Vancomycin Use
In the 50 study ICUs, the rates of vancomycin use during
the pre-intervention period (Figure 1, plotted circles) were
similar in range to the 113 ICARE Phase 2 ICUs contributing
data to the national aggregate benchmark report (Figure 1, box
plots). The overall (pooled mean) ICU-specific use of vanco-
mycin in the 50 ICUs at the 20 study hospitals after the inter-
vention was 89.1 defined daily doses per 1,000 patient-days, a
2.8% increase over the pre-intervention rate of use (86.6
defined daily doses per 1,000 patient-days). Despite this
increase in aggregate usage among all ICUs, most ICUs
reported lower rates of vancomycin use after the intervention
compared with the pre-intervention rates. The median differ-
ence was -3 defined daily doses per 1,000 patient days (range
-138 to +196), but this difference was not statistically signifi-
cant.
Differences in the rate of vancomycin use varied substan-
tially by the type of practice change. ICUs in which unit-spe-
cific programs were implemented used significantly lower
rates of vancomycin in the postintervention period than in the
pre-intervention period (Table), including both ICU-specific
educational in-service (mean difference of -35.8 vs. +7.6,
defined daily doses per 1,000 patient-days, p=0.01) and
removal of vancomycin as routine surgical prophylaxis for
cardiac surgery (mean difference -66.9 vs. +4.2 defined daily
doses per 1,000 patient-days, p=0.01). In the multivariable
Figure 1. Boxplot of benchmark data of vancomycin use at all Phase 2
Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE)
hospitals (n=113 intensive-care units [ICUs]) in October 1997, by type
of ICU (18). ICU types include pediatric (P), coronary (C), combined
medical-surgical (MS), neurosurgical (NS), surgical (S), and cardiotho-
racic (CT). For each type of ICU, boxes represent rates of vancomycin
use at the 25th–75th percentiles (interquartile range), and ends of verti-
cal lines represent values at the 10th–90th percentiles. Horizontal lines
represent median values in each ICU type. Additionally, plotted circles
represent the rate of vancomycin use in the pre-intervention period
(1996–1997) in the 50 ICUs participating in the intervention study, and
open circles represent the 10 ICUs reporting a prescriber practice
change identified in the specific unit (i.e., ICU-specific practice change)
(1 burn ICU not shown). DDD, defined daily doses.Emerging Infectious Diseases  •  Vol. 8, No. 7, July 2002 705
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analysis in which data were adjusted for each ICU and changes
in MRSA prevalence, ICUs in which unit-specific practices
were identified for improvement used, on average, 49 fewer
daily doses of vancomycin per 1,000 patient days than did the
other ICUs (parameter estimate -48.5; 95% confidence limits -
68.8, -28.22; p=0.0001), compared to pre-intervention levels.
The ICUs reported a 35%–37% decrease in median vancomy-
cin use (median 132 daily doses of vancomycin per 1,000
patient days for unit-specific education and 149 for removal of
prophylaxis) (Table). Analyses were repeated by using the rel-
ative change of each parameter rather than difference in rates,
with similar results of statistical significance. 
VRE and MRSA
Thirty-five (70%) of the 50 study ICUs tested at least 10
isolates of enterococci for vancomycin susceptibility and were
included in the calculations of VRE prevalence during both
pre- and postintervention periods. During the pre-intervention
period, these ICUs reported a median VRE prevalence of
11.7%. Overall, VRE prevalence increased during the postin-
tervention period compared with the pre-intervention period
among all study ICUs (median difference +2.3%; range –41%
to +32%), although this difference was not statistically signifi-
cant. However, when compared by type of practice change, the
difference in VRE prevalence was significantly lower in ICUs
in which unit-specific practice changes occurred, compared
with other ICUs (mean difference -7.5% vs. +5.7%, p<0.001).
Although many of the ICUs with decreases in vancomycin use
reported increases in percent VRE, all the ICUs noting a unit-
specific practice change reported decreases in both percent
VRE and vancomycin use (Figure 2). Analysis of these data by
using either the relative change in percent VRE or vancomycin
use obtained results of similar statistical significance. How-
ever, since the relative changes were commonly of extreme
values (range 0–400%), these are not reported here.
Because vancomycin use is associated with prevalence of
MRSA in ICUs (19), we also evaluated temporal trends in
MRSA prevalence. During the pre-intervention period, these
ICUs reported a median MRSA prevalence of 33.5%. Overall,
prevalence of MRSA increased during the postintervention
period compared with the pre-intervention period in all study
ICUs (mean difference +5.5%; range –22% to +38%; p=0.02).
The increase in MRSA prevalence was similar in ICUs report-
ing unit-specific practice change compared with other ICUs
(mean difference +2.7% vs. +7.1%, p=0.39).
Discussion
In this study involving 50 ICUs from 20 hospitals, we
evaluated the effect of inter-institution benchmarking of van-
comycin use on reducing vancomycin use and prevalence of
VRE. Our study suggests that hospital personnel can use local
monitoring data, interpreted in the context of a risk-adjusted
external benchmark, to help direct their efforts to reduce
excessive use of antimicrobial drugs and reduce antimicrobial
resistance. Having access to these data empowered the hospital
personnel to make recommendations directed at the specific
ICU. Our study further suggests that focused efforts (i.e, ICU
specific) may be a more effective means to reduce excessive
vancomycin use than hospitalwide activities. 
The external benchmarks used were risk adjusted (i.e.,
stratified by ICU type) to account for the different rates of van-
comycin used by different types of ICUs (18). Comparison of
local data to a risk-adjusted benchmark should make the com-
parison more relevant (and more believable) to the ICU staff
responsible for prescribing and other patient-care activities.
Although several health-care reform proposals suggest some
form of interfacility comparisons and public reporting of these
types of data (21,22), caution must be exercised by ensuring
that the comparisons are risk adjusted. We think part of the
success of this study was that risk-adjusted comparisons were
Table. Prescribing practice changes implemented in response to benchmark data intervention, and mean rate of vancomycin usea before and 
after intervention, 50 Project ICARE ICUs, January 1996–July 1999b
Vancomycin use prescribing practice change
No. of ICUs (%)
Vancomycin use before and after benchmark data intervention
p valuec
Change absent Change present
(n=50) Before After Before After
Hospitalwided 22 (44%)
Drug use evaluation 19 (38%) 74.2  80.5  105.3 94.1 0.62
Redistributed HICPAC guidelines on VRE  9 (18%) 79.4  84.6  116.0 90.6 0.34
Prior approval of vancomycin required 3 (6%) 87.2  99.4 84.7  67.2 0.25
Unit-specificd 11 (22%)
ICU-specific education on appropriate 
vancomycin use 
9 (18%) 75.9  96.3 83.3  132.1 0.01
Removed vancomycin from surgical 
prophylaxis 
3 (6%) 82.0  82.2 85.9  149.1 0.01
aDefined daily doses per 1,000 patient-days. 
bAbbreviations: ICARE, Intensive Care Antimicrobial Resistance Epidemiology; ICU, intensive-care units; HICPAC, Healthcare Infection control Practices Advisory Committee; 
VRE, vancomycin-resistant enterococci.
cPaired t-test.
dComponents of each major categories are not mutually exclusive, so one ICU may be represented in several components of each category.RESEARCH
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provided, rather than an overall single benchmark for all ICU
types or all hospitals combined. These comparisons allowed
hospital personnel to target unit-specific practice changes to
particular ICU areas identified as having an excessive amount
of vancomycin used compared with similar types of ICUs in
the national benchmark. The reasons unit-specific change in
prescriber practice in ICUs were associated with decreases in
vancomycin use and VRE are not certain. The impact of the
unit-specific practice changes may actually result from engag-
ing local opinion leaders, as has been successfully done in
other quality improvement projects (23,24). 
Our study suggests that benchmarking rates of antimicro-
bial use, feedback on these rates, and changes in practice can
lead to changes in antimicrobial use. However, the use of some
overlapping practice changes and the absence of randomiza-
tion may limit the ability to generalize the specific practice
changes described in this study. In addition, hospitals began
activities to reduce vancomycin use through changes in pre-
scriber practice independent of the investigation. In fact, sev-
eral of the ICUs that used unit-specific changes had the highest
rates of vancomycin use, and this excessive use may have
made the ICU staff more receptive to the change. These identi-
fied changes may not have been successful if implemented in
ICUs in which the usage of vancomycin had not been as exces-
sive. This theory may be true but does not detract from the
major finding of this study: participation in a monitoring pro-
gram with comparisons to a valid benchmark provided useful
data and allowed the hospital to implement an effective change
in practice. In addition, the retrospective nature of ascertaining
the description of changes in prescriber practice may involve
some recall bias. However, this study demonstrates how a
monitoring system provides the tools for hospitals to make
rational, valid decisions about initiating activities to change
prescribing practices of vancomycin. One aspect of a quality
improvement project that was missing from this study was the
ability of the infection-control staff to share quality improve-
ment protocols or ideas with other institutions participating in
the monitoring system, as has been reported in other quality
improvement studies using benchmarking (9).
Our study suggests that interpreting local data in the con-
text of a risk-adjusted benchmark can aid in quality improve-
ment decisions. Many of the study hospitals are continuing to
voluntarily report data on antimicrobial use and antimicrobial
resistance to CDC’s NNIS system as part of a continued qual-
ity improvement process. As hospital information systems
become more automated, aggregating data such as these
should become commonplace. Understanding how to best
benchmark and respond to these data will be critical in our
efforts to reduce antimicrobial-resistant infections.
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